Skip to main content
Top

Cancer Immunology, Immunotherapy

Issue 8/2002

Content (7 Articles)

Original Article

Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response

Christiane Wack, Annette Kirst, Jürgen C. Becker, Werner K. Lutz, Eva-B. Bröcker, Wolfgang H. Fischer

Perspectives

Antitumor vaccines: is it possible to prevent a tumor?

Pier-Luigi Lollini, Guido Forni

Original Article

Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model

Tetsuro Kikuchi, Yasuharu Akasaki, Toshiaki Abe, Tsuneya Ohno

Original Article

Influence of adenoviral vector on expression of angiogenesis regulating factors in non-small cell lung cancer cell lines

Hartmut Kuhn, Alexander Riedel, Wolfram Eichler, Gabriele Aust, Christian Gessner, Hubert Wirtz

Original Article

Large-scale expansion of CD3+CD56+ lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants

A. Gritzapis, D. Dimitroulopoulos, E. Paraskevas, C. Baxevanis, M. Papamichail

Original Article

Comparison of the TCR ζ-chain with the FcR γ-chain in chimeric TCR constructs for T cell activation and apoptosis

Lifen Ren-Heidenreich, Ryan Mordini, Thomas G. Hayman, Ruth Siebenlist, Ann LeFever

Original Article

Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer

Stephen D. Gillies, Yan Lan, Bea Brunkhorst, Wai-Keung Wong, Yue Li, Kin-Ming Lo

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine